Gayatri Dabadghao retweetledi

🚨Another practice-changing study at #ASCO23
🌟DUO-O/@GOG 3025 demonstrates improved progression free survival in pts w/ HR deficient AND proficient advanced stage #OvarianCancer treated with durvalumab + olaparib + bevacizumab
#gyncsm #ImmunoOnc




English

























